open access
Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage
open access
Abstract
Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.
Abstract
Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.
Keywords
cardiotoxicity, molecular target therapy, arterial hypertension, cardiac failure, arrhythmias, drug side-effects
About this articleTitle
Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
34-40
Published online
2017-08-24
Page views
728
Article views/downloads
878
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2017;67(1):34-40.
Keywords
cardiotoxicity
molecular target therapy
arterial hypertension
cardiac failure
arrhythmias
drug side-effects
Authors
Beata Jagielska
Konrad Tałasiewicz
Aleksandra Czachowska
Katarzyna Gepner
Elżbieta Mądro
Małgorzata Symonides
Paweł Wiechno
Maciej Krzakowski